Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Patients' and healthcare providers' views on dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia: a qualitative study

  • At: PPR 2022 (2022)
  • Type: Poster
  • By: DJODIKROMO, Melissa (Radboudumc)
  • Co-author(s): Melissa Djodikromo, PhD Student, Radboud university medical centre, Department of Haematology, Radboud Institute for Health Sciences, The Netherlands
    Charlotte Bekker, Radboud university medical centre, Department of Pharmacy, Radboud Institute for Health Sciences, The Netherlands
    Nicole Blijlevens
  • Abstract:

    Introduction: Dose reduction of tyrosine kinase inhibitors for patients with chronic myeloid leukaemia (CML) in molecular remission seems promising to reduce adverse events while maintaining therapeutic effectiveness. Successful dose reduction demands a patient-centred approach, meeting their concerns and needs. This study identified patients’ and healthcare providers’ views on dose reduction, including preferences for a patient decision aid.

    Methods: Semi-structured interviews were conducted via video call with eighteen adult CML patients and healthcare providers (six haematologists, four nurses, and two pharmacists). Participants were questioned about perceived (dis)advantages of dose reduction, factors patients and healthcare providers considered when making the decision to reduce TKI dose, and preferences for a patient decision aid including content and format. Data were thematically analysed.

    Results: Most interviewees supported dose reduction. Reduced adverse events, lower medication costs, and “feeling less patient” due to less medication intake were prominent perceived advantages. Participants were mainly concerned about disease recurrence and loss of molecular response. Information about personal possibilities for dose reduction and potential consequences and risks was considered essential to make a well-informed decision. Interviewees preferred such information in an online patient decision aid.

    Conclusions: Patients and healthcare providers were generally positive about TKI dose reduction. An online patient decision aid could support the decision making process.

Last update 4 October 2019

FIP Congresses